El agonismo GIP potencia el efecto incretnico y anorexiante de GLP-1 a nivel central, reduciendo el desarrollo de nuseas (tabla 2)1,3,5
Diabetes Care 2017 , 40 , 821831
Trial status: Active, not recruiting Clinical Trials Identifier: NCT06077864 Trial Name: A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE - CVOT) Diabetes Type: Adults with overweight or obesity who have weight-related health conditions with or without type 2 diabetes Trial Sponsor: Boehringer Ingelheim What is the aim of the study
doi: 10.1016/0016-5085(86)90936-4 Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery
But its benefits continue beyond there
States like Louisiana, Michigan, and Ohio, are pursing legal action to ban this practice due to the prevalence and rising costs of prescription drugs